ReviewLipids in health and disease2020
Low-density lipoprotein cholesterol lowering treatment: the current approach.
Review in Lipids in health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Mendelian randomization studies of lifestyle-related risk factors for stroke: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- A meta-analysis of the pooled impact ofFrontiers in genetics · 2023Pooled it
- A real-world analysis of Lomitapide-associated adverse events: Data from FAERS and CVAROD.Medicine · 2025Article
- Assessing LDL-C Levels and Lipid-Modifying Therapies in a Real-World Cohort of Patients with Atherosclerotic Cardiovascular Disease: The REALITY Study.Journal of clinical medicine · 2025Article
- Impact of plant-derived antioxidants on heart aging: a mechanistic outlook.Frontiers in pharmacology · 2025Review
- Clinical significance of serum Helicobacter pylori antibody cytotoxin-associated gene A levels in patients with unstable angina.European journal of medical research · 2024Article
- Advances in Pharmacological Approaches for Managing Hypercholesterolemia: A Comprehensive Overview of Novel Treatments.Biomedicines · 2024Review
- In Silico Characterization ofACS omega · 2023Article
- A Picrocrocin-Enriched Fraction from a Saffron Extract Affects Lipid Homeostasis in HepG2 Cells through a Non-Statin-like Mode.International journal of molecular sciences · 2023Article
- Psoriasis comorbid with atherosclerosis meets in lipid metabolism.Frontiers in pharmacology · 2023Review
- AGR2-induced cholesterol synthesis drives lovastatin resistance that is overcome by combination therapy with allicin.Acta pharmacologica Sinica · 2022Article
- Impact of Pulmonary Hypertension on Mortality after Surgery for Aortic Stenosis.Medicina (Kaunas, Lithuania) · 2022Article
- Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes.Medicina (Kaunas, Lithuania) · 2022Review
- Multifunctional exosomes derived from bone marrow stem cells for fulfilled osseointegration.Frontiers in chemistry · 2022Review
- High-Risk Polymorphisms Associated with the Molecular Function of Human HMGCR Gene Infer the Inhibition of Cholesterol Biosynthesis.BioMed research international · 2022Article
- Evaluation of the Therapeutic Pattern and Pharmaco-Utilization in Hypercholesterolemic Patients Treated with Statins: A Retrospective Study on Italian Real-World Data.Risk management and healthcare policy · 2022Article
- Simultaneous point-of-care testing of blood lipid profile and glucose: Performance evaluation of the GCare Lipid Analyzer.Journal of clinical laboratory analysis · 2021Article
- Polypharmacy in the Management of Arterial Hypertension-Friend or Foe?Medicina (Kaunas, Lithuania) · 2021Article
- Predictive value of immunological markers in systemic sclerosis.Experimental and therapeutic medicine · 2021Article
- Inflammatory and Biomechanical Drivers of Endothelial-Interstitial Interactions in Calcific Aortic Valve Disease.Circulation research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last 50 years, several clinical and epidemiological studies during have shown that increased levels of low-density lipoprotein cholesterol (LDLc) are associated with the development and progression of atherosclerotic lesions. The discovery of β-Hydroxy β-methylglutaryl-CoA reductase inhibitors (statins), that possess LDLc-lowering effects, lead to a true revolution in the prevention and treatment of cardiovascular diseases. Statins remain the cornerstone of LDLc-lowering therapy. Lipid-lowering drugs, such as ezetimibe and bile acid sequestrants, are prescribed either in combination with statins or in monotherapy (in the setting of statin intolerance or contraindications to statins). Microsomal triglyceride transfer protein inhibitors and protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are other drug classes which have been investigated for their potential to decrease LDLc. PCSK9 have been approved for the treatment of hypercholesterolemia and for the secondary prevention of cardiovascular events. The present narrative review discusses the latest (2019) guidelines of the European Atherosclerosis Society/European Society of Cardiology for the management of dyslipidemia, focusing on LDLc-lowering drugs that are either already available on the market or under development. We also consider "whom, when and how" do we treat in terms of LDLc reduction in the daily clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.